Search research articles
Contact Us
Filters
Showing results (51-60 of 69) with videos related to
Page
of 7
Sort By:
Cancer Chemotherapy and Pharmacology
|
May 27, 2023
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)
Tsukasa Hasegawa, Ryo Ariyasu, Hisashi Tanaka, et al.
The Oncologist
|
October 26, 2019
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, et al.
Thoracic Cancer
|
November 21, 2022
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01)
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, et al.
Thoracic Cancer
|
September 9, 2024
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902)
Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, et al.
JTO Clinical and Research Reports
|
December 4, 2023
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2024
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, et al.
Translational Lung Cancer Research
|
July 11, 2026
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, et al.
JTO Clinical and Research Reports
|
June 19, 2025
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
Hidenobu Ishii, Koichi Azuma, Yuta Yamanaka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 19, 2025
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)
Hiroaki Akamatsu, Shinya Sakata, Koichi Azuma, et al.
Molecular Cancer
|
October 29, 2025
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer
Ritsu Ibusuki, Eiji Iwama, Atsushi Shimauchi, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 69) with videos related to
Sort By:
Page
of 7
Cancer Chemotherapy and Pharmacology
|
May 27, 2023
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)
Tsukasa Hasegawa, Ryo Ariyasu, Hisashi Tanaka, et al.
The Oncologist
|
October 26, 2019
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, et al.
Thoracic Cancer
|
November 21, 2022
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01)
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, et al.
Thoracic Cancer
|
September 9, 2024
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902)
Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, et al.
JTO Clinical and Research Reports
|
December 4, 2023
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2024
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, et al.
Translational Lung Cancer Research
|
July 11, 2026
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, et al.
JTO Clinical and Research Reports
|
June 19, 2025
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
Hidenobu Ishii, Koichi Azuma, Yuta Yamanaka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 19, 2025
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)
Hiroaki Akamatsu, Shinya Sakata, Koichi Azuma, et al.
Molecular Cancer
|
October 29, 2025
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer
Ritsu Ibusuki, Eiji Iwama, Atsushi Shimauchi, et al.
Page
of 7